Acute Changes in Plasma Glucose and Cardiovascular Disease in Diabetes

Exclusion Criteria

• •Arrhythmia diagnosed prior to the screening visit
• •Implantable cardioverter defibrillator (ICD) or pacemaker at the time of inclusion
• •Severe heart failure (left ventricular ejection fraction \<25%)
• •Structural heart disease (Wolf-Parkinson-White syndrome, congenital heart disease, severe valve disease)
• •Thyroid dysfunction (except for well-regulated eltroxin substituted myxoedema)
• •Anemia (male: hemoglobin \<8.0; female: hemoglobin \<7.0 mmol/l)
• •Hypo-Heart 2:
• •Arrhythmia diagnosed prior to or at the time of inclusion
• •Implantable cardioverter defibrillator (ICD) or pacemaker at the time of inclusion
• •Severe heart failure (left ventricular ejection fraction \<25%)
• •Structural heart disease (Wolf-Parkinson-White syndrome, congenital heart disease, severe valve disease)
• •Insulin naïve patients with type 2 diabetes
• •Thyroid dysfunction (except for well-regulated eltroxine substituted myxoedema)
• •Unable to comply with daily CGM during run-in period
• •Anemia (male: hemoglobin \< 8.0; female: hemoglobin \< 7.0 mmol/l)
• •Type 1 or type 2 diabetes
• •Prediabetes (HbA1c \>42 mmol/l and/or fasting plasma glucose \>6.1 mmol/l)
• •Family history of diabetes (type 1 og type 2 diabetes)
• •Arrhythmia diagnosed prior to or at the time of inclusion
• •ICD or pacemaker at the time of inclusion
• •Severe heart failure (left ventricular ejection fraction \<25%)
• •Structural heart disease (Wolf-Parkinson-White syndrome, congenital heart disease, severe valve disease)
• •Thyroid dysfunction (except for well-regulated eltroxine substituted myxoedema)
• •Anemia (male: hemoglobin \< 8.0; female: hemoglobin \< 7.0 mmol/l)
• •Rapid-Heart:
• •Arrhythmia diagnosed prior to or at the time of the screening visit
• •ECG with left or right bundle branch block diagnosed prior to the screening visit.
• •Implantable cardioverter defibrillator or pacemaker at the time of inclusion
• •Heart failure diagnosed prior to the screening visit (left ventricular ejection fraction \< 45%)
• •Structural heart disease (Wolf-Parkinson-White syndrome, congenital heart disease, severe valve disease)
• •Thyroid dysfunction (except for well-regulated myxoedema)
• •Anaemia (male: haemoglobin \<8.0 mmol/l; female: haemoglobin \<7.0 mmol/l)
• •Treatment with anticoagulant or antiplatelet treatment
• •Bleeding disorder diagnosed prior to the screening visit